Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$113.07

0.33 (0.29%)

06:33
11/25/16
11/25
06:33
11/25/16
06:33

Johnson & Johnson: NICE reverses decision on CDF leukaemia drug after price drop

Hundreds of people could benefit as NICE decision means ibrutinib can come off the Cancer Drugs Fund and be routinely available to treat chronic lymphocytic leukaemia. Ibrutinib will be available as a routine option for an estimated 620 patients with chronic lymphocytic leukaemia who have had treatment before, or who have genetic changes - known as 17p deletion or TP53 mutation. An earlier recommendation by NICE did not recommend ibrutinib, also known as Imbruvica, for routine NHS use. However, following a reduction in price, the independent appraisal committee were able to approve the drug as cost effective. Reference Link

JNJ Johnson & Johnson
$113.07

0.33 (0.29%)

10/18/16
UBSW
10/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson robust pipeline underappreciated, says UBS
UBS analyst Matt Miksic said the Johnson & Johnson pipeline remains robust and is underappreciated. The analyst said the recent launch of biosimilars removes uncertainty and should be positive for the stock. He also expects the additional deployment of the company's capital - to expand its pipeline through in-licensing, partnerships or mid-sized acquisitions - to be incremental to his Buy thesis. Miksic has a $137 price target on Johnson & Johnson shares.
10/19/16
LEER
10/19/16
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson should be bought on weakness, says Leerink
Leerink analyst Danielle Antalffy believes the recent selloff in Johnson & Johnson's shares was overdone and would recommend buying on weakness. The analyst views the company as well-equipped to manage the inevitable Remicade headwind and continues to believe Johnson & Johnson can drive improving top-line growth in 2017. She reiterates an Outperform rating and $140 price target on the shares.
10/19/16
UBSW
10/19/16
NO CHANGE
Target $144
UBSW
Buy
Johnson & Johnson has potential upside from expanding pipeline, says UBS
UBS analyst Matt Miksic noted Johnson & Johnson delivered a solid quarter and said he believes there is upside to his Buy thesis. The analyst cited the company's expanding pipeline, capital allocation strategy, and contracting across its broad portfolio and patient assistance programs is expected to help mitigate pressure from biosimilar competition. Miksic reiterated his Buy rating and raised his price target to $144 from $137 on Johnson & Johnson shares.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Johnson & Johnson should be bought on recent weakness, says RBC Capital
After meeting with J&J's VP, Investor Relations, RBC Capital analyst Glenn Novarro says that the company's Q3 pharma results indicate that the growth of its major drugs can more than offset any declines in Remicade sales next year. The analyst quotes J&J as saying that it has not been using price hikes to increase its sales, and he thinks that the company's diverse business model will allow it to avoid being hurt by any regulatory pressures. He is upbeat on the company's efforts to increase its margins and notes that its medical device results have improved. Novarro keeps a $133 price target and an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

FBC

Flagstar Bancorp

$28.69

0.31 (1.09%)

06:32
04/25/17
04/25
06:32
04/25/17
06:32
Earnings
Flagstar Bancorp reports Q1 EPS 46c, consensus 38c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 23

    May

NLSN

Nielsen

$41.59

0.59 (1.44%)

06:31
04/25/17
04/25
06:31
04/25/17
06:31
Earnings
Nielsen reports Q1 EPS 20c, consensus 48c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

  • 03

    May

  • 31

    May

SVU

Supervalu

$3.85

0.01 (0.26%)

06:31
04/25/17
04/25
06:31
04/25/17
06:31
Earnings
Supervalu reports Q4 adjusted EPS 13c, consensus 9c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BHI

Baker Hughes

$58.65

0.97 (1.68%)

06:30
04/25/17
04/25
06:30
04/25/17
06:30
Earnings
Baker Hughes reports Q1 adjusted EPS (4c), consensus (21c) »

Reports Q1 revenue $2.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LLY

Eli Lilly

$83.42

1.53 (1.87%)

06:29
04/25/17
04/25
06:29
04/25/17
06:29
Hot Stocks
Eli Lilly backs FY17 EPS view of $4.05-$4.15, consensus $4.11 »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

WHR

Whirlpool

$174.80

3.29 (1.92%)

06:28
04/25/17
04/25
06:28
04/25/17
06:28
Hot Stocks
Whirlpool sees about $300M of raw material inflation in 2017 »

Says had sort-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

CAPR

Capricor Therapeutics

$3.09

0.08 (2.66%)

06:28
04/25/17
04/25
06:28
04/25/17
06:28
Conference/Events
Capricor Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

LLY

Eli Lilly

$83.42

1.53 (1.87%)

06:27
04/25/17
04/25
06:27
04/25/17
06:27
Earnings
Eli Lilly reports Q1 EPS 98c, consensus 96c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

WEGRY

Weir Group

$12.91

0.71 (5.82%)

06:27
04/25/17
04/25
06:27
04/25/17
06:27
Upgrade
Weir Group rating change  »

Weir Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DD

DuPont

$79.37

0.72 (0.92%)

06:26
04/25/17
04/25
06:26
04/25/17
06:26
Hot Stocks
Breaking Hot Stocks news story on DuPont »

DuPont up 2.1% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FOX

21st Century Fox

$29.75

-0.47 (-1.56%)

, FOXA

21st Century Fox

$30.35

-0.35 (-1.14%)

06:25
04/25/17
04/25
06:25
04/25/17
06:25
Periodicals
Former presenter names Fox News executives in new lawsuit, FT says »

Andrea Tantaros, a former…

FOX

21st Century Fox

$29.75

-0.47 (-1.56%)

FOXA

21st Century Fox

$30.35

-0.35 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 15

    Jun

CTSH

Cognizant

$58.89

1.04 (1.80%)

06:24
04/25/17
04/25
06:24
04/25/17
06:24
Recommendations
Cognizant analyst commentary  »

Cognizant fundamentals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

  • 09

    May

  • 12

    May

  • 31

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

ST

Sensata

$42.76

1.71 (4.17%)

06:16
04/25/17
04/25
06:16
04/25/17
06:16
Earnings
Sensata sees FY17 adjusted EPS $3.08-$3.20, consensus $3.14 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 09

    May

PRGS

Progress Software

$29.73

0.24 (0.81%)

06:16
04/25/17
04/25
06:16
04/25/17
06:16
Hot Stocks
Progress Software appoints Dmitri Tcherevik to Chief Technology Officer »

Progress announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:15
04/25/17
04/25
06:15
04/25/17
06:15
General news
FX Action: EUR-JPY rallied to a fresh one-month peak »

FX Action: EUR-JPY…

ST

Sensata

$42.76

1.71 (4.17%)

06:13
04/25/17
04/25
06:13
04/25/17
06:13
Earnings
Sensata sees Q2 adjusted EPS 70c-80c, consensus 81c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 09

    May

GIII

G-III Apparel

$24.35

0.76 (3.22%)

, SMRT

Stein Mart

06:13
04/25/17
04/25
06:13
04/25/17
06:13
Periodicals
Stein Mart selling Ivanka Trump clothing under different label, WSJ reports »

Ivanka Trump clothing was…

GIII

G-III Apparel

$24.35

0.76 (3.22%)

SMRT

Stein Mart

JWN

Nordstrom

$47.23

-0.39 (-0.82%)

M

Macy's

$29.19

-0.29 (-0.98%)

DDS

Dillard's

$54.38

0.44 (0.82%)

TJX

TJX

$78.62

0.06 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

TECK

Teck Resources

$21.96

0.17 (0.78%)

06:13
04/25/17
04/25
06:13
04/25/17
06:13
Earnings
Teck Resources reports Q1 EPS C$1.16 vs. C$0.03 last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

PPG

PPG

$108.01

2.07 (1.95%)

, AKZO

Akzo Nobel

06:13
04/25/17
04/25
06:13
04/25/17
06:13
Periodicals
Dutch Economic Affairs Minister still opposes Akzo Nobel takeover, Reuters says »

Dutch Economic Affairs…

PPG

PPG

$108.01

2.07 (1.95%)

AKZO

Akzo Nobel

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ST

Sensata

$42.76

1.71 (4.17%)

06:12
04/25/17
04/25
06:12
04/25/17
06:12
Earnings
Sensata reports Q1 adjusted EPS 71c, consensus 68c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 09

    May

AMZN

Amazon.com

$907.41

8.88 (0.99%)

06:10
04/25/17
04/25
06:10
04/25/17
06:10
Downgrade
Raymond James downgrades Amazon with shares up 21% this year »

Raymond James analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 16

    May

  • 23

    May

PPBI

Pacific Premier

$36.75

0.7 (1.94%)

06:10
04/25/17
04/25
06:10
04/25/17
06:10
Earnings
Pacific Premier reports Q1 EPS 34c, consensus 42c »

First quarter results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

RDWR

Radware

$15.42

0.25 (1.65%)

06:10
04/25/17
04/25
06:10
04/25/17
06:10
Hot Stocks
Radware reports cash and equivalents $316M as of March 31 »

As of March 31 the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

06:10
04/25/17
04/25
06:10
04/25/17
06:10
General news
FX Action: EUR-JPY rallied to a fresh one-month peak »

FX Action: EUR-JPY…

CAPR

Capricor Therapeutics

$3.09

0.08 (2.66%)

06:09
04/25/17
04/25
06:09
04/25/17
06:09
Hot Stocks
Capricor announces 'positive' six-month results from Phase I/II HOPE trial »

Capricor Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.